145 assets in Metastatic Neoplasm

Azacytidine

azd1390

Bl-M07D1

CD47/SIRPA-BLOCKING AGENT ALX148

cd70-targeting car-t cells

Cea Car-T Cells

cht101

esg406

Fam-Trastuzumab Deruxtecan-Nxki

Favezelimab

fda018-adc

G 207

Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide

Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody, Conjugated At Glutaminyl Residues To Monomethylauristatin E (Mmae), With A Ratio Of 1 To 2, Via A Cleavable Linker

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

mk-8294

Ncp-Cd47 Sirna Intratumorally

nkt3447

nkt3964

Saruparib

Tolododekin Alfa

Vibostolimab

Yttrium (90 Y)

Zanidatamab

ak114

Codalytic

Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)

Loxo-435

ly4175408

ly4257496

mk-6837

sph5030

Zongertinib

Dordaviprone

afm24

ans03

cr-001

Pd-L1 Car-T Cells

Shr-4602

sim0237

Syha1813

Tak-280